Co-Authors
This is a "connection" page, showing publications co-authored by Massimo Puoti and Alessio Aghemo.
Connection Strength
0.254
-
Italian association for the study of the liver position statement on SARS-CoV2 vaccination. Dig Liver Dis. 2021 06; 53(6):677-681.
Score: 0.059
-
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. J Hepatol. 2019 12; 71(6):1106-1115.
Score: 0.052
-
Real life experiences in HCV management in 2018. Expert Rev Anti Infect Ther. 2019 02; 17(2):117-128.
Score: 0.050
-
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. Infection. 2018 Oct; 46(5):607-615.
Score: 0.048
-
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet Gastroenterol Hepatol. 2017 06; 2(6):427-434.
Score: 0.044